Andlauer Healthcare Group Inc.

DB:3LT Stock Report

Market Cap: €1.2b

Andlauer Healthcare Group Valuation

Is 3LT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3LT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3LT (€28.6) is trading below our estimate of fair value (€65.3)

Significantly Below Fair Value: 3LT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3LT?

Key metric: As 3LT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3LT. This is calculated by dividing 3LT's market cap by their current earnings.
What is 3LT's PE Ratio?
PE Ratio25.7x
EarningsCA$65.50m
Market CapCA$1.68b

Price to Earnings Ratio vs Peers

How does 3LT's PE Ratio compare to its peers?

The above table shows the PE ratio for 3LT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.4x
SYAB SYNLAB
28.1x-11.4%€2.5b
FME Fresenius Medical Care
18.8x19.3%€12.4b
RHK RHÖN-KLINIKUM
18.6x7.5%€836.7m
NXU Nexus
44.2x17.1%€1.2b
3LT Andlauer Healthcare Group
25.7xn/a€1.7b

Price-To-Earnings vs Peers: 3LT is good value based on its Price-To-Earnings Ratio (25.7x) compared to the peer average (27.4x).

Price to Earnings Ratio vs Industry

How does 3LT's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
3LT 25.7xIndustry Avg. 18.7xNo. of Companies10PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 3LT is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the European Healthcare industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is 3LT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3LT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 3LT's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3LT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€28.60
€31.75
+11.0%
8.7%€36.09€28.07n/a6
Nov ’25€26.60
€31.34
+17.8%
8.6%€35.22€27.91n/a6
Oct ’25€25.40
€32.11
+26.4%
7.6%€35.40€28.06n/a7
Sep ’25€25.80
€32.11
+24.5%
7.6%€35.40€28.06n/a7
Aug ’25€26.80
€32.11
+19.8%
7.6%€35.40€28.06n/a7
Jul ’25€25.80
€33.39
+29.4%
10.1%€39.17€27.69n/a7
Jun ’25€24.40
€33.39
+36.8%
10.1%€39.17€27.69n/a7
May ’25€27.40
€34.75
+26.8%
9.6%€39.58€29.34n/a7
Apr ’25€28.80
€34.37
+19.3%
9.4%€39.36€29.18n/a7
Mar ’25€26.80
€34.47
+28.6%
12.9%€42.74€28.27n/a7
Feb ’25€26.40
€34.08
+29.1%
12.9%€42.26€27.95n/a7
Jan ’25€26.80
€34.00
+26.9%
13.5%€42.40€28.04n/a7
Dec ’24€26.60
€32.99
+24.0%
13.7%€41.45€27.41n/a7
Nov ’24€25.80
€35.90
+39.1%
13.8%€42.46€30.13€26.606
Oct ’24€27.60
€37.20
+34.8%
12.8%€43.69€31.01€25.407
Sep ’24€29.40
€36.22
+23.2%
11.5%€42.09€30.55€25.807
Aug ’24€29.60
€37.54
+26.8%
10.9%€42.12€31.25€26.807
Jul ’24€29.80
€38.44
+29.0%
10.4%€42.91€31.84€25.807
Jun ’24€31.00
€38.13
+23.0%
8.5%€42.02€33.89€24.407
May ’24€33.40
€39.07
+17.0%
6.1%€41.98€35.88€27.407
Apr ’24€32.80
€38.23
+16.6%
8.2%€41.58€32.19€28.807
Mar ’24€32.20
€38.48
+19.5%
8.6%€42.73€32.39€26.806
Feb ’24€32.60
€38.48
+18.0%
8.6%€42.73€32.39€26.406
Jan ’24€32.00
€41.53
+29.8%
5.8%€44.18€38.29€26.805
Dec ’23€36.40
€41.53
+14.1%
5.8%€44.18€38.29€26.605
Nov ’23€37.80
€41.35
+9.4%
5.8%€44.04€38.07€25.805

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%